SOM Biotech attended the BIO International Convention 2020 in its virtual format “BIO Digital” on June 8th – 12th. The virtual gathering, one of the most relevant venues for the biotech industry worldwide, allowed SOM biotech to hold more than 70 meetings with key potential business partners and identify opportunities for future drug discovery and …

SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company. Raul Insa: “As CEO and founding partner of a growing biotech company, I have led …

SOM Biotech will attend BIO International Convention 2020 in its virtual format “BIO Digital” on June 8th – 12th. The virtual gathering of the biotech industry will be one of the largest venues to be celebrated in 2020. It will allow companies to access key partners to explore opportunities and share the latest drug discovery …

SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment for infectious disease, but the situation is exceptional. “Our technology works based on chemical structure and we are looking for products available on the …

Interested in learning more about the role of Artificial Intelligence in Healthcare? Angelo Dalli, AI expert and serial tech entrepreneur, and Raúl Insa, CEO of SOM Biotech, will share their experience and thoughts on this topic at the webinar organized by EBAN – European Business Angels Network. The webinar will take place on the 12th …

“Actualidad Economica” is the dean magazine of the Spanish economic press, founded in 1958. In the interview with the journal, Raúl tells about SOM Biotech creation, focus, and the objectives of the company. He describes the main development pipeline of SOM Biotech, and outline the expertise of its team. Raúl also reveals the most valuable …

SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) …

While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 …

SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead the pipeline development with a special focus …

SOM Biotech will attend the Eyeforpharma Barcelona event that will be hosted online due to the impact of COVID-19, between March 31st and April 2nd 2020. Maria Zimina – Business Development Manager – underlines: “We look forward to having the opportunity to share and discuss with potential business partners and specialized investors the progress made …